Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer

被引：0
|
作者：
Fessler, Beate
机构：
来源：
BREAST CARE | 2023年 / 18卷 / 02期
关键词：
D O I：
10.1159/000530539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15
    Modi, Shanu
    Salgado, Roberto
    Guarneri, Valentina
    Alagappan, Divi
    Dennis, Natalie
    Newell, Amy Hanlon
    Boran, Aislyn
    Morsli, Ouzna
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Tsurutani, J.
    Jacot, W.
    Yamashita, T.
    Riaz, F.
    Yerushalmi, R.
    Im, S-A.
    Niikura, N.
    Halser-Strub, U.
    Cortes, J.
    Wennstig, A-K.
    Chae, Y.
    Wang, X.
    Li, W.
    Simon, H.
    Masci, G.
    Tamburini, E.
    Aguilar, C. Orbegoso
    Tecson, K.
    Yung, L.
    Modi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S342 - S343
  • [43] EXPOSURE-RESPONSE OF TRASTUZUMAB DERUXTECAN (T-DXD) IN SUBJECTS WITH HER2-LOW METASTATIC BREAST CANCER
    Lu, Z.
    Li, H.
    Wada, R.
    Li, L.
    Kamiyama, E.
    Vaddady, P.
    Abutarif, M.
    Garimella, T.
    Khatri, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S87 - S87
  • [44] Safety and Efficacy of Combined Trastuzumab-Deruxtecan and Concurrent Radiation Therapyin Breast Cancer: The TENDANCE Multicentric French Study (Trastuzumab-Deruxtecan and Concurrent Radiation Therapy in Breast Cancer)
    Debbi, K.
    Benderra, M. A.
    Medioni, J.
    Durdux, C.
    Asmahane, B.
    Monnier, L.
    Gligorov, J.
    Assaf, E.
    Belkacemi, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S103 - S103
  • [45] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
    Modi, Shanu
    Niikura, Naoki
    Yamashita, Toshinari
    Jacot, William
    Sohn, Joohyuk
    Tokunaga, Eriko
    Vidal, Maria Jesus
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yeesoo
    Ueno, Naoto T.
    Prat, Aleix
    Suto, Fumitaka
    Kuwahara, Yusuke
    McEwen, Robert
    Feng, Wenqin
    Goto, Hiroki
    Orbegoso, Cecilia
    Cameron, David A.
    Tsurutani, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Visualizing trastuzumab-deruxtecan action in HER2+breast cancer cells at nanoscale
    Cortese, K.
    Garrone, O.
    Gagliani, M. C.
    Bellese, G.
    Arnaldi, P.
    Abbona, A.
    Paccagnella, M.
    Ruatta, F.
    Merlano, M. C.
    Castagnola, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S197 - S197
  • [47] Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
    Bartsch, Rupert
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 901 - 910
  • [48] A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Modi, Shanu
    Ohtani, Shoichiro
    Lee, Caleb
    Wang, Yibin
    Saxena, Kapil
    Cameron, David A.
    CANCER RESEARCH, 2020, 80 (04)
  • [49] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [50] Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer
    Shimomura, Akihiko
    Takano, Toshimi
    Takahashi, Shunji
    Sagara, Yasuaki
    Watanabe, Junichiro
    Tokunaga, Eriko
    Shinkai, Tetsu
    Kamio, Takahiro
    Kikumori, Kunika
    Kamiyama, Emi
    Fujisaki, Yoshihiko
    Saotome, Dan
    Yamashita, Toshinari
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (01) : 160 - 169
12345